

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 6, 2008

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of Registrant as specified in its charter)

Delaware 0-26224 51-0317849
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization) Identification No.)

311 Enterprise Drive
Plainsboro, NJ 08536
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (609) 275-0500

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01 OTHER EVENTS

On June 6, 2008, Integra LifeSciences Holdings Corporation (the "Company") received formal notice from The NASDAQ Stock Market LLC ("NASDAQ") that, following the filing of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2008 with the Securities and Exchange Commission, the Company satisfies all requirements for continued listing on The NASDAQ Global Market and that it determined to continue the listing of the Company's securities on NASDAQ.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

99.1 Press release, dated June 6, 2008, issued by Integra LifeSciences Holdings Corporation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

Date: June 6, 2008

By: /s/ John B. Henneman, III

John B. Henneman, III
Executive Vice President,
Finance and Administration,
and Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
-----	-----
99.1	Press Release, dated June 6, 2008, issued by Integra LifeSciences Holdings Corporation.

News Release

Contacts:

Integra LifeSciences Holdings Corporation

John B. Henneman, III
Executive Vice President
Finance and Administration
and Chief Financial Officer
(609) 936-2481
jhenneman@Integra-LS.com

Kathryn Lamping
Assistant General Counsel
(609) 936-2276
kathryn.lamping@Integra-LS.com

Integra LifeSciences Receives NASDAQ Notice of Compliance

PLAINSBORO, N.J., June 6, 2008 (PRIME NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART) today announced that The NASDAQ Stock Market has formally notified the Company that, following the filing of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2008 with the Securities and Exchange Commission, the Company satisfies all requirements for continued listing on The NASDAQ Global Market and that it has determined to continue the listing of the Company's securities on NASDAQ.

"We are pleased with NASDAQ's decision," said Stuart Essig, Integra's President and Chief Executive Officer. "We look forward to a continued positive working relationship with The NASDAQ Stock Market."

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at (<http://www.Integra-LS.com>).

IART-G

Source: Integra LifeSciences Holdings Corporation